Biotech News

Personalis Brings Resistance Mutation Tracking to NeXT Personal® MRD Test

Personalis (PSNL)PersonalisCommercial

Real-Time Variant Tracker™ supplemental results track resistance and therapeutically targetable variants as cancer biology evolves. FREMONT, Calif. --(BUSINESS WIRE)--Oct. 20, 2026-- Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the commercial launch of

Related news

Personalis

Precision-Oncology Genomics Personalis develops genomic tests for cancer detection, monitoring and therapy development. Its platform uses highly sensitive sequencing and tumor-informed analysis to identify minimal residual disease. NeXT Personal NeXT Personal is a personalized circulating-tumor-DNA test designed to detect and track...

Recent company news

Stock data

Close
14.72 USD
Market cap
1.17B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States